Education
About Us
Working with TipRanks
Follow Us
OmniAb (OABI)
NASDAQ:OABI
OABI Stock Chart & Stats
$1.59
-$0.06(-1.65%)
At close: 4:00 PM EST
$1.59
-$0.06(-1.65%)
Day’s Range― - ―
52-Week Range$1.22 - $4.87
Previous CloseN/A
Volume80.31K
Average Volume (3M)561.73K
Market Cap
$234.65M
Enterprise Value$164.87M
Total Cash (Recent Filing)$41.62M
Total Debt (Recent Filing)$21.78M
Price to Earnings (P/E)―
Beta1.22
Next Earnings
Nov 04, 2025EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.15
Shares Outstanding143,955,400
10 Day Avg. Volume481,153
30 Day Avg. Volume561,725
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.70
Enterprise Value/Revenue7.16
Enterprise Value/Gross Profit9.10
Enterprise Value/Ebitda-3.10
Forecast
1Y Price Target
$7.33Price Target Upside361.01% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Bulls Say, Bears Say
Bulls Say
Financial PerformanceSteady financial results and new license agreements are factors in maintaining a Buy rating for the stock, with a price target representing over 100% potential share price appreciation.
Pipeline ProgressOmniAb has added new discovery licenses and increased its roster of active programs, indicating strong growth and development.
Research And DevelopmentAnalyst maintains a Buy rating on OABI shares due to the long-term potential of the Company's broad partnered R&D pipeline.
Bears Say
Revenue DeclineQ2 revenues of $3.9M included OABI's first xPloration revenues, but overall revenues declined by 49% year over year.
Revenue GuidanceManagement reaffirmed FY25 revenues guidance with a potential downside, citing challenges in predicting drug discovery partner revenues.
Revenue PerformanceThe company reported revenue of $3.9 million compared to our estimate of $5.4 million and consensus of $5.3 million.
OmniAb News
OABI FAQ
What was OmniAb’s price range in the past 12 months?
OmniAb lowest stock price was $1.22 and its highest was $4.87 in the past 12 months.
What is OmniAb’s market cap?
OmniAb’s market cap is $234.65M.
When is OmniAb’s upcoming earnings report date?
OmniAb’s upcoming earnings report date is Nov 04, 2025 which is in 6 days.
How were OmniAb’s earnings last quarter?
OmniAb released its earnings results on Aug 06, 2025. The company reported -$0.15 earnings per share for the quarter, missing the consensus estimate of -$0.149 by -$0.001.
Is OmniAb overvalued?
According to Wall Street analysts OmniAb’s price is currently Undervalued.
Does OmniAb pay dividends?
OmniAb does not currently pay dividends.
What is OmniAb’s EPS estimate?
OmniAb’s EPS estimate is -0.14.
How many shares outstanding does OmniAb have?
OmniAb has 143,955,400 shares outstanding.
What happened to OmniAb’s price movement after its last earnings report?
OmniAb reported an EPS of -$0.15 in its last earnings report, missing expectations of -$0.149. Following the earnings report the stock price went down -2.591%.
Which hedge fund is a major shareholder of OmniAb?
Currently, no hedge funds are holding shares in OABI
OmniAb Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.33 (361.01% Upside)
$7.33 (361.01% Upside)
Hedge Fund Trend
Decreased
By 108.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 13.9%
Last 30 Days ▲ 13.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-59.21%
12-Months-Change
Fundamentals
Return on Equity
-22.84%
Trailing 12-Months
Asset Growth
-12.33%
Trailing 12-Months
Company Description
OmniAb
OmniAb (OABI) is a biotechnology company specializing in the discovery and development of fully human monoclonal antibodies. The company operates within the biopharmaceutical sector, focusing on providing innovative therapeutic solutions for various diseases. OmniAb's proprietary platform leverages advanced technologies to generate high-quality antibodies that can be used in drug development, catering to the needs of pharmaceutical companies and research institutions seeking to create targeted treatments.
OABI Company Deck
OABI Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Despite a notable decrease in quarterly revenue and increased net loss, OmniAb showed strong momentum in partnerships and active programs, with high potential future milestones and successful technology launches, suggesting a positive outlook.View all OABI earnings summariesOABI Stock 12 Month Forecast
Average Price Target
$7.33
▲(361.01% Upside)
Technical Analysis
Cartesian Therapeutics
―
Tiziana Life Sciences
―
Atea Pharmaceuticals
―
Vor Biopharma
―
Sagimet Biosciences, Inc. Class A
―
Ownership Overview
5.61% Insiders
10.60% Mutual Funds
1.95% Other Institutional Investors
74.90% Public Companies and
Individual Investors